Zota Health Care LImited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ZOTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zota Health Care reported Q1 FY26 (quarter ended June 30, 2025) results with strong standalone growth. Standalone revenue from operations rose ~49% YoY to Rs. 7,800.70 lakhs (vs Rs. 5,220.36 lakhs), and standalone profit after tax surged ~273% YoY to Rs. 590.44 lakhs (vs Rs. 158.43 lakhs), driving EPS to Rs. 2.03 from Rs. 0.60. However, the consolidated picture is starkly different: consolidated revenue grew to Rs. 10,358.26 lakhs but the company slipped into a higher loss after tax of Rs. (1,377.79) lakhs versus Rs. (1,272.39) lakhs, reflecting heavy losses at subsidiaries, especially Davaindia Health Mart. During the quarter, the company issued 7,95,000 equity shares on a preferential basis at Rs. 900/share, allotted shares on warrant conversions, granted 67,500 ESOPs, and infused Rs. 4,924.42 lakhs into Davaindia. Statutory auditors (Pradeep K. Singhi & Associates) issued an unmodified limited review report with no qualifications.
Standalone numbers signal a healthy core pharmaceutical business, but the widening consolidated loss underscores the cash burn from the Davaindia retail expansion. Shareholders should monitor subsidiary-level break-even progress; near-term consolidated EPS remains negative despite the strong standalone showing.